396 related articles for article (PubMed ID: 6370987)
1. The use of depot neuroleptics: clinical experience in the United States.
Kane JM
J Clin Psychiatry; 1984 May; 45(5 Pt 2):5-12. PubMed ID: 6370987
[TBL] [Abstract][Full Text] [Related]
2. Depot fluphenazine: risk/benefit ratio.
Glazer WM
J Clin Psychiatry; 1984 May; 45(5 Pt 2):28-35. PubMed ID: 6370986
[TBL] [Abstract][Full Text] [Related]
3. Depot neuroleptics: the relevance of psychosocial factors--a United States perspective.
Hogarty GE
J Clin Psychiatry; 1984 May; 45(5 Pt 2):36-42. PubMed ID: 6143746
[TBL] [Abstract][Full Text] [Related]
4. The risk/benefit ratio of depot neuroleptics: a Scandinavian perspective.
Dencker SJ
J Clin Psychiatry; 1984 May; 45(5 Pt 2):22-7. PubMed ID: 6143744
[TBL] [Abstract][Full Text] [Related]
5. Antipsychotic medication: clinical guidelines for maintenance therapy.
Johnson DA
J Clin Psychiatry; 1985 May; 46(5 Pt 2):6-15. PubMed ID: 2859281
[TBL] [Abstract][Full Text] [Related]
6. Depot neuroleptics: a comparative review of standard, intermediate, and low-dose regimens.
Kane JM; Woerner M; Sarantakos S
J Clin Psychiatry; 1986 May; 47 Suppl():30-3. PubMed ID: 2871014
[TBL] [Abstract][Full Text] [Related]
7. [Results of long-term treatment with depot neuroleptics in schizophrenic patients].
Klein A; Ehle G
Psychiatr Neurol Med Psychol (Leipz); 1988 Mar; 40(3):159-67. PubMed ID: 3132729
[TBL] [Abstract][Full Text] [Related]
8. Dose response of prophylactic antipsychotics.
Davis JM; Kane JM; Marder SR; Brauzer B; Gierl B; Schooler N; Casey DE; Hassan M
J Clin Psychiatry; 1993 Mar; 54 Suppl():24-30. PubMed ID: 8097195
[TBL] [Abstract][Full Text] [Related]
9. Relapse and rehospitalization: comparing oral and depot antipsychotics.
Schooler NR
J Clin Psychiatry; 2003; 64 Suppl 16():14-7. PubMed ID: 14680414
[TBL] [Abstract][Full Text] [Related]
10. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
[TBL] [Abstract][Full Text] [Related]
11. Discontinuation of oral and depot fluphenazine in schizophrenic patients after one year of continuous medication: a controlled study.
Levine J; Schooler NR; Severe J; Escobar J; Gelenberg A; Mandel M; Sovner R; Steinbook R
Adv Biochem Psychopharmacol; 1980; 24():483-93. PubMed ID: 6996445
[No Abstract] [Full Text] [Related]
12. [Clinical experience with depot neuroleptic treatment].
Waldmann KD; Neumann J
Z Arztl Fortbild (Jena); 1984; 78(20):853-6. PubMed ID: 6523910
[No Abstract] [Full Text] [Related]
13. An open clinical trial with the long-acting neuroleptics flupenthixol decanoate and fluphenazine decanoate in the maintenance treatment of schizophrenia.
Kong DS; Yeo SH
Pharmatherapeutica; 1989; 5(6):371-9. PubMed ID: 2687894
[TBL] [Abstract][Full Text] [Related]
14. A depot neuroleptic withdrawal study. A controlled study of the clinical effects of the withdrawal of depot fluphenazine decanoate and depot flupenthixol decanoate in chronic schizophrenic patients.
Wistedt B
Acta Psychiatr Scand; 1981 Jul; 64(1):65-84. PubMed ID: 7032224
[TBL] [Abstract][Full Text] [Related]
15. The effect of age on the pharmacological management of ambulatory patients treated with depot neuroleptic medications for schizophrenia and related psychotic disorders.
Mamo DC; Sweet RA; Chengappa KN; Reddy RR; Jeste DV
Int J Geriatr Psychiatry; 2002 Nov; 17(11):1012-7. PubMed ID: 12404650
[TBL] [Abstract][Full Text] [Related]
16. Lithium augmentation fails to reduce symptoms in poorly responsive schizophrenic outpatients.
Schulz SC; Thompson PA; Jacobs M; Ninan PT; Robinson D; Weiden PJ; Yadalam K; Glick ID; Odbert CL
J Clin Psychiatry; 1999 Jun; 60(6):366-72. PubMed ID: 10401914
[TBL] [Abstract][Full Text] [Related]
17. Clinical effectiveness of oral and parenteral rapid neuroleptization.
Coffman JA; Nasrallah HA; Lyskowski J; McCalley-Whitters M; Dunner FJ
J Clin Psychiatry; 1987 Jan; 48(1):20-4. PubMed ID: 3542982
[TBL] [Abstract][Full Text] [Related]
18. Risks versus benefits of different types of long-acting injectable antipsychotics.
McEvoy JP
J Clin Psychiatry; 2006; 67 Suppl 5():15-8. PubMed ID: 16822092
[TBL] [Abstract][Full Text] [Related]
19. Plasma levels of neuroleptic in patients receiving depot fluphenazine.
Cohen BM; Waternaux C; Chouinard G; Sommer BR; Jones B
J Clin Psychopharmacol; 1985 Dec; 5(6):328-32. PubMed ID: 4066997
[TBL] [Abstract][Full Text] [Related]
20. Comparative effectiveness of fluphenazine decanoate injections every 2 weeks versus every 6 weeks.
Carpenter WT; Buchanan RW; Kirkpatrick B; Lann HD; Breier AF; Summerfelt AT
Am J Psychiatry; 1999 Mar; 156(3):412-8. PubMed ID: 10080557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
